AVAglio: Phase 3 Trial of Bevacizumab Plus Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Multiforme

被引：148

作者：

Chinot, O. L. ^{[1
]}

Rouge, T. de la Motte ^{[2
]}

Moore, N. ^{[3
]}

Zeaiter, A. ^{[3
]}

Das, A. ^{[4
]}

Phillips, H. ^{[4
]}

Modrusan, Z. ^{[4
]}

Cloughesy, T. ^{[5
]}

机构：

[1] Univ Mediterranee, Ctr Hosp Univ Timone, Serv Neurooncol, F-13385 Marseilles 05, France

[2] Grp Hosp Pitie Salpetriere, Med Oncol Serv, F-75634 Paris, France

[3] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland

[4] Genentech Inc, San Francisco, CA 94080 USA

[5] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

来源：

ADVANCES IN THERAPY | 2011年 / 28卷 / 04期

关键词：

bevacizumab; clinical trial; glioblastoma multiforme; phase; 3; ENDOTHELIAL GROWTH-FACTOR; RADIATION-THERAPY; IRINOTECAN; COMBINATION; PROGRESSION; PACLITAXEL;

D O I：

10.1007/s12325-011-0007-3

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Despite treatment with the current standard-of-care therapies, patients with newly diagnosed glioblastoma multiforme (GBM) exhibit dismal prognoses. Bevacizumab has demonstrated activity in patients with recurrent GBM and phase 2 trials indicate that the combination of bevacizumab with standard-of-care therapy is feasible and active for patients with newly diagnosed GBM. Bevacizumab has been granted US approval for use as single-agent therapy for patients with progressive GBM following prior therapy, although it has not received approval for use in patients with GBM in Europe. Phase 3 studies have been initiated in patients with newly diagnosed GBM and are currently recruiting patients. We describe the protocol for the AVAglio phase 3 registration trial, which is designed to evaluate the efficacy and safety of combining bevacizumab with standard-of-care therapy in patients with newly diagnosed GBM.

引用

页码：334 / 340

页数：7

共 50 条

[1] AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
O. L. Chinot
T. de La Motte Rouge
N. Moore
A. Zeaiter
A. Das
H. Phillips
Z. Modrusan
T. Cloughesy
[J]. Advances in Therapy, 2011, 28 : 334 - 340
[2] AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
Chinot, O. L.
Wick, W.
Saran, F.
Mason, W. P.
Henriksson, R.
Nishikawa, R.
Zeaiter, A. H.
Moore, N.
Das, A.
Cloughesy, T. F.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[3] Bevacizumab in Combination With Radiotherapy and Temozolomide for PatientsWith Newly Diagnosed Glioblastoma Multiforme
van Linde, Myra E.
Verhoeff, Joost J. C.
Richel, Dirk J.
van Furth, Bwouter R.
Reijneveld, Jaap C.
Verheul, Henk M. W.
Stalpers, Lukas J. A.
[J]. ONCOLOGIST, 2015, 20 (02): : 107 - 108
[4] Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma
Schiff, David
Huse, Jason
Wen, Patrick
[J]. NEURO-ONCOLOGY, 2014, 16 (06) : 769 - 769
[5] Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Chinot, Olivier L.
Wick, Wolfgang
Mason, Warren
Henriksson, Roger
Saran, Frank
Nishikawa, Ryo
Carpentier, Antoine F.
Hoang-Xuan, Khe
Kavan, Petr
Cernea, Dana
Brandes, Alba A.
Hilton, Magalie
Abrey, Lauren
Cloughesy, Timothy
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (08): : 709 - 722
[6] Radiotherapy, temozolomide, and bevacizumab followed by irinotecan, temozolomide and bevacizumab in newly diagnosed glioblastoma multiforme: Preliminary results front an ongoing phase II trial
Kirkpatrick, J. P.
Desjardins, A.
Reardon, D. A.
Vredenburgh, J. J.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S209 - S209
[7] Radiologic progression types are treatment specific: An exploratory analysis of a phase 3 study of bevacizumab plus radiotherapy plus temozolomide for patients with newly diagnosed glioblastoma (AVAglio).
Nowosielski, Martha
Chinott, Olivier L.
Radbrucht, Alexander
Stockhammer, Guenther
Garcia, Josep
Revil, Cedric
Nishikawa, Ryo
Mason, Warren P.
Henriksson, Roger
Saran, Frank
Bendszus, Martin
Abrey, Lauren E.
Cloughesy, Timothy Francis
Wick, Wolfgang
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[8] Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM)
Nishikawa, Ryo
Saran, Frank
Mason, Warren
Wick, Wolfgang
Cloughesy, Timothy Francis
Henriksson, Roger
Hilton, Magalie
Garcia, Josep
Vogt, Tobias
Pallaud, Celine
Chinot, Oliver L.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[9] Efficacy and safety of bevacizumab (By) plus standard combination temozolomide (T) and radiotherapy (RI) in newly diagnosed glioblastoma: Final results from AVAglio
Wick, W.
Cloughesy, T.
Henrikkson, R.
Saran, F.
Mason, W.
Nishikawa, R.
Hilton, M.
Abrey, L.
Chinot, O.
[J]. ONKOLOGIE, 2013, 36 : 94 - 94
[10] Efficacy and safety of bevacizumab (By) plus standard combination temozolomide (T) and radiotherapy (RT) in newly diagnosed glioblastoma: final results from AVAglio
Chinot, O.
Cloughesy, T.
Henriksson, R.
Saran, F.
Mason, W.
Nishikawa, R.
Hilton, M.
Abrey, L.
Wick, W.
[J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S774 - S775

← 1 2 3 4 5 →